share_log

Oppenheimer Assumes Evaxion Biotech at Outperform, Announces Price Target of $16

Oppenheimer Assumes Evaxion Biotech at Outperform, Announces Price Target of $16

奥本海默假设Evaxion Biotech表现跑赢大盘,宣布目标股价为16美元
Benzinga Real-time News ·  2022/07/18 10:34

Oppenheimer analyst Jeff Jones assumes Evaxion Biotech (NASDAQ:EVAX) with a Outperform rating and announces Price Target of $16.

奥本海默分析师杰夫·琼斯假设Evaxion Biotech(纳斯达克股票代码:EVAX)的评级为跑赢大盘,并宣布目标股价为16美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发